Litigation Details for Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

Docket		Date Filed	2010-12-14
Court	District Court, D. Delaware	Date Terminated	2013-03-30
Cause	28:1338 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	7,132,570; RE37,516
Link to Docket	External link to docket

Details for Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-12-14				External link to document

Cephalon, Inc. v. Apotex Corp., 1:10-cv-01078: Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Cephalon, Inc. v. Apotex Corp., No. 1:10-cv-01078, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware concerning Apotex’s proposed generic version of Cephalon’s Provigil product, which contains modafinil. The case formed part of Cephalon’s broader effort to delay generic competition to Provigil.

The dispute was resolved through a settlement rather than a merits judgment. Apotex did not obtain an immediate unfettered launch opportunity, and the case did not produce a reported trial decision invalidating or upholding the asserted Provigil patents. The commercial significance of the case came from its place in Cephalon’s coordinated settlement strategy with multiple generic applicants.

What drug and generic product were at issue?

The case concerned modafinil tablets, marketed by Cephalon as Provigil for narcolepsy, obstructive sleep apnea-related excessive sleepiness, and shift-work sleep disorder.

Field	Details
Brand drug	Provigil
Active ingredient	Modafinil
Brand company	Cephalon, Inc.
Generic applicant	Apotex Corp.
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:10-cv-01078
Case type	Hatch-Waxman patent infringement action
Commercial issue	Timing of generic modafinil entry

Apotex’s ANDA filing created a statutory basis for litigation under the Hatch-Waxman Act. A Paragraph IV certification would have asserted that one or more patents listed for Provigil were invalid, unenforceable, or not infringed. Cephalon’s complaint triggered the statutory 30-month stay of FDA approval, subject to the applicable regulatory and litigation record. [1][2]

What patents protected Provigil and modafinil?

The principal patent associated with Provigil’s commercial protection was U.S. Patent No. 5,618,845, commonly called the ’845 patent. The patent was directed to modafinil and related pharmaceutical use or composition claims that Cephalon relied on to protect Provigil from generic competition.

Patent	Relevance to Provigil	Approximate ordinary expiration
U.S. Patent No. 4,927,855	Earlier modafinil compound protection	2008
U.S. Patent No. 5,618,845	Core Provigil-related protection	October 2014
Pediatric exclusivity	FDA extension associated with listed protection	April 2015

The ’845 patent’s ordinary expiration was extended by six months of pediatric exclusivity. That extension became commercially important because it placed the effective end of core regulatory protection in 2015, even though the underlying patent expired in 2014. [2][3]

Cephalon also pursued formulation, particle-size, and related patent strategies around Provigil. Those patents created additional litigation leverage, but the core commercial barrier was the patent estate associated with modafinil and the regulatory exclusivity period.

What did the ’845 patent cover?

The ’845 patent was central to Cephalon’s Provigil litigation program. Its claims were directed to pharmaceutical compositions and methods involving modafinil. The patent did not provide permanent protection for all uses of modafinil. Its value came from the ability to assert listed claims against ANDA applicants seeking approval for the same active ingredient and dosage form.

The patent’s strategic importance was reduced by the absence of long-term compound protection. Modafinil’s earlier compound patent had already expired. Cephalon therefore relied on later-issued patents, pediatric exclusivity, litigation timing, and settlement restrictions to manage generic entry.

When did Cephalon sue Apotex?

Cephalon filed the Delaware action in 2010 after Apotex submitted an ANDA containing a Paragraph IV certification directed to Provigil-related patent protection. The civil action number identifies the case as 1:10-cv-01078.

The filing placed Apotex within Cephalon’s wider Provigil litigation campaign. Cephalon sued several generic applicants after they sought FDA approval for modafinil tablets. The cases were strategically connected because an early generic launch by one applicant could materially affect the market value of all remaining Provigil patent claims.

The Apotex action did not proceed to a publicly reported final judgment on patent validity or infringement. The litigation ended through settlement and dismissal.

What was the outcome of Cephalon v. Apotex?

The case was resolved by settlement and subsequently dismissed. The settlement terms were not fully disclosed in the public docket.

The available public record supports the following conclusions:

1. Apotex did not receive an immediate unrestricted right to market generic modafinil as a result of the litigation.
2. The parties avoided a full trial on infringement, validity, and enforceability.
3. The settlement was part of the broader resolution framework Cephalon used with Provigil generic applicants.
4. The case did not establish a precedential ruling on the validity of the principal Provigil patents.
5. The settlement delayed the need for a judicial determination of whether Apotex’s ANDA product infringed the asserted claims.

Confidential settlements create a material information limitation for competitive analysis. Unless the agreement or regulatory filings disclose the license date, launch date, payment terms, or restrictions, the precise economic value of the Apotex settlement cannot be determined from the docket alone.

Did Apotex agree to a delayed generic launch?

Yes. The Provigil settlements generally involved delayed generic entry, with launch rights tied to a negotiated date before the expiration of the remaining patent and pediatric-exclusivity period.

Public reporting concerning Cephalon’s Provigil settlements identified April 2012 as the principal negotiated entry date for several generic companies. Generic modafinil competition began in 2012, well before the ordinary expiration of the ’845 patent. [4][5]

The settlement structure allowed Cephalon to preserve several years of branded sales while granting generic companies an earlier entry date than they might have received through litigation alone. The commercial effect was a controlled transition from monopoly pricing to generic competition.

Because the Apotex agreement was not fully public, its precise launch mechanics should not be treated as identical to every other Provigil settlement. The broader market record, however, places Apotex within the group of generic applicants whose commercial access was governed by negotiated entry restrictions rather than an immediate at-risk launch.

What was the FDA Orange Book status of Provigil?

The FDA Orange Book listed patent and exclusivity information for Provigil and its approved strengths. The core Orange Book analysis involved:

• The listed patents associated with modafinil products.
• The expiration date of the ’845 patent.
• The six-month pediatric-exclusivity extension.
• The 30-month stay triggered by Paragraph IV litigation.
• FDA approval timing for ANDAs filed by generic applicants.

The Orange Book did not eliminate the need for litigation. It provided the statutory framework that enabled Cephalon to sue and delay approval while the patent dispute was pending.

FDA exclusivity timeline

Event	Timing
Modafinil compound protection ends	2008
’845 patent expiration	October 2014
Pediatric exclusivity expiration	April 2015
Generic modafinil entry under settlements	2012
Cephalon’s effective exclusivity period	Ended before 2015 through negotiated entry

The key distinction is between patent expiration and market entry. Generic entry occurred in 2012 through settlements even though the principal patent and pediatric exclusivity extended beyond that date.

How did the Apotex case compare with other Provigil litigation?

Cephalon’s broader Provigil strategy involved multiple ANDA applicants, including Teva, Mylan, Ranbaxy, and other generic manufacturers. The cases shared common commercial characteristics but did not necessarily involve identical ANDA formulations or identical patent claims.

Issue	Apotex case	Broader Provigil litigation
Product	Generic modafinil tablets	Generic modafinil tablets
Legal pathway	Hatch-Waxman Paragraph IV action	Multiple parallel Paragraph IV actions
Primary patent strategy	Asserted Provigil-related patents	Core, formulation, and related patents
Disposition	Settlement and dismissal	Primarily settlements
Public merits ruling	None of decisive commercial significance	Limited compared with settlement activity
Entry result	Delayed, negotiated entry	Coordinated generic entry beginning in 2012

The absence of a trial judgment reduced legal precedent but increased the importance of settlement economics. Cephalon avoided the risk of invalidation, while generic companies secured a defined commercial entry opportunity.

Which companies challenged Cephalon’s Provigil patents?

Several generic manufacturers challenged Provigil’s patent protection through ANDA filings and Paragraph IV certifications. Publicly reported participants included:

• Apotex Corp.
• Teva Pharmaceuticals
• Mylan Pharmaceuticals
• Ranbaxy Laboratories
• Other ANDA applicants involved in related Provigil proceedings

Teva’s role was particularly important because Teva later acquired Cephalon in 2011. That transaction gave Teva access to Cephalon’s branded portfolio while leaving the existing Provigil settlement framework and generic-entry issues commercially relevant. [6]

What was the commercial impact of the litigation?

Provigil was a major Cephalon revenue product before generic competition. Cephalon’s 2010 annual report reported substantial Provigil sales and identified generic challenges as a principal business risk. [7]

The litigation had four commercial effects:

1. It extended the period during which Cephalon could sell Provigil without broad generic competition.
2. It converted uncertain litigation outcomes into negotiated entry dates.
3. It preserved the possibility of branded revenue through the early 2010s.
4. It exposed Cephalon to antitrust scrutiny over reverse-payment or pay-for-delay settlement arrangements.

Generic entry in 2012 materially changed the market. Once multiple generic manufacturers entered, pharmacy substitution and price competition reduced Provigil’s revenue base. The value of the Apotex settlement therefore depended less on the nominal patent expiration date than on the number, timing, and terms of all generic settlements.

Did the settlement create antitrust risk?

Yes. Cephalon’s Provigil settlements later became the subject of Federal Trade Commission scrutiny and private antitrust litigation. The FTC alleged that Cephalon paid or otherwise compensated generic companies to delay entry. The central issue was whether the settlements were legitimate resolutions of patent disputes or unlawful agreements to postpone generic competition. [4][8]

The antitrust analysis focused on:

• Whether value transferred from Cephalon to generic applicants.
• Whether the generic companies had meaningful evidence of patent invalidity or noninfringement.
• Whether the settlement delayed entry beyond the date justified by the patent dispute.
• Whether the agreements restricted generic competition without corresponding patent-based justification.

The existence of a patent infringement action did not immunize the settlement from antitrust review. The economic substance of the agreement, rather than its litigation caption, controlled the competition analysis.

How strong was Cephalon’s Provigil patent estate?

Cephalon’s estate was commercially effective but legally time-limited.

Strengths

• The ’845 patent provided a basis for ANDA litigation.
• The FDA listing enabled use of the Hatch-Waxman 30-month stay.
• Pediatric exclusivity extended the effective protection period.
• Multiple related patent positions increased settlement leverage.
• Cephalon’s market position gave generic applicants an incentive to negotiate entry rights.

Weaknesses

• The original modafinil compound patent had expired.
• The remaining protection was later-issued and therefore closer to expiration.
• A successful invalidity or noninfringement ruling could have accelerated entry.
• Multiple generic challenges increased litigation and antitrust exposure.
• Settlement-based protection could not prevent eventual multi-source generic competition.

The estate was strong enough to support delayed entry but not strong enough to prevent generic access permanently. Its principal weakness was the limited remaining patent term when the major ANDA challenges arrived.

What generic launch risks existed for Provigil?

The principal risks were:

Risk	Effect
At-risk launch	Immediate price erosion and potential damages exposure
Invalidity ruling	Early generic approval and loss of patent leverage
Noninfringement ruling	Same commercial result as invalidity
Multiple settlements	Coordinated entry and rapid erosion after launch
Antitrust liability	Damages and restrictions on future settlement strategy
Formulation differences	Reduced ability to rely on formulation claims

Cephalon managed those risks through serial litigation and negotiated settlements. Apotex’s case therefore had greater strategic value as part of a portfolio than as an isolated lawsuit.

What is the current legal significance of the case?

The case is principally significant as a Provigil Hatch-Waxman settlement matter. It did not generate a major reported opinion establishing a new rule on claim construction, patent validity, inequitable conduct, or ANDA infringement.

For due diligence, the key legal conclusions are:

• The case was resolved without a merits judgment.
• The settlement controlled Apotex’s market-entry timing.
• The asserted patent strategy was linked to the Provigil/modafinil patent estate.
• The case should be analyzed with the related Cephalon generic cases and FTC proceedings.
• The public docket does not provide a complete economic picture of the settlement.

Key Takeaways

• Cephalon v. Apotex, No. 1:10-cv-01078, was a Delaware Hatch-Waxman case involving generic modafinil and Cephalon’s Provigil product.
• The dispute ended in settlement and dismissal rather than a public trial judgment.
• U.S. Patent No. 5,618,845 was the principal patent associated with Provigil protection.
• The ’845 patent expired in October 2014, with pediatric exclusivity extending protection to April 2015.
• Generic Provigil entry began through negotiated settlements in 2012.
• The settlement delayed Apotex’s unrestricted market entry but did not prevent eventual generic competition.
• The case formed part of the broader Cephalon Provigil settlement strategy later examined in antitrust proceedings.
• The patent estate had meaningful short-term litigation strength but limited long-term durability because compound protection had already expired.

FAQs

Was Apotex the first generic company to launch Provigil?

No. Generic modafinil competition began in 2012 through settlements involving multiple generic applicants. Apotex was one participant in the broader Provigil litigation and settlement structure.

Did Cephalon win a patent trial against Apotex?

No publicly reported merits judgment established a Cephalon victory over Apotex in this action. The case ended through settlement and dismissal.

Did the Apotex settlement invalidate the Provigil patents?

No. A settlement does not invalidate a patent and does not establish that the patent would have survived a final validity challenge.

Did Provigil have biologic or biosimilar exclusivity issues?

No. Provigil was a small-molecule drug containing modafinil. The relevant competitors were ANDA-based generic manufacturers, not biosimilar applicants.

Did Teva’s acquisition of Cephalon affect the Apotex case?

Teva acquired Cephalon in 2011. The transaction changed ownership of the Provigil portfolio and consolidated branded and generic strategic interests, but it did not convert modafinil into a biologic or alter the Hatch-Waxman character of the Apotex dispute.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
2. Cephalon, Inc. v. Apotex Corp., No. 1:10-cv-01078, U.S. District Court for the District of Delaware.
3. U.S. Patent and Trademark Office. (1987). U.S. Patent No. 5,618,845: Modafinil pharmaceutical compositions.
4. Federal Trade Commission. (2015). FTC v. Cephalon, Inc., No. 2:08-cv-02141, U.S. District Court for the Eastern District of Pennsylvania.
5. Federal Trade Commission. (2012). In re Cephalon, Inc., administrative and competition materials concerning Provigil settlements.
6. Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon.
7. Cephalon, Inc. (2011). 2010 annual report.
8. U.S. Supreme Court. (2013). FTC v. Actavis, Inc., 570 U.S. 136.